Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly

News Daily News

ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly

December 22, 2022

ACS Care in Older Patients Entails Unique Risks, Shifting Goals, Says AHA

News Daily News

ACS Care in Older Patients Entails Unique Risks, Shifting Goals, Says AHA

December 16, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

TCTMD’s Top 10 Most Popular Stories for November 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

December 01, 2022

The FIGARO-DKD Trial

Podcast TCTMD Talking Points

The FIGARO-DKD Trial

November 23, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

News Conference News EACTS 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

Michael O'Riordan

October 12, 2022

CV Risk Factors or Preexisting CVD: What’s Worse for COVID-19?

News Daily News

CV Risk Factors or Preexisting CVD: What’s Worse for COVID-19?

October 11, 2022

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

News Daily News

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

Michael O'Riordan

October 05, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

NSTEMI Patients With CKD: Early Invasive vs Delayed Strategy Similar for Survival

News Daily News

NSTEMI Patients With CKD: Early Invasive vs Delayed Strategy Similar for Survival

October 03, 2022

TCT 99: Short- and Long-term Outcomes of Patients with Chronic Kidney Disease Undergoing Protected High-risk Percutaneous Coronary Intervention

Presentation TCT 2022

TCT 99: Short- and Long-term Outcomes of Patients with Chronic Kidney Disease Undergoing Protected High-risk Percutaneous Coronary Intervention

Presenter: Arsalan Abu-Much

September 18, 2022

New-Onset AF Not Uncommon After Mitral TEER

News Daily News

New-Onset AF Not Uncommon After Mitral TEER

September 13, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

September 2022 News Roundup

News Opinion CV Team Dispatch

September 2022 News Roundup

September 01, 2022

International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches - Chronic Kidney Disease EXTENDed Follow-up: Survival at 5 years of Follow-up

Presentation ESC 2022

International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches - Chronic Kidney Disease EXTENDed Follow-up: Survival at 5 years of Follow-up

Presenter: Sripal Bangalore

August 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.